Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25912039 | 0.95 | RAPGEF4 (0.58) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL18583900 | 0.90 | RAPGEF4 (0.52) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL12377130 | 0.89 | NPC1 (0.62) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL1673420 | 0.88 | RAPGEF4 (0.67) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL15152202 | 0.88 | RAPGEF4 (0.53) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL8810023 | 0.86 | CYP26A1 (0.53) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL8386481 | 0.85 | NPC1 (0.57) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL3476199 | 0.83 | EGFR (0.52) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL8634550 | 0.83 | RAPGEF4 (0.62) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 | |
| SCHEMBL14981731 | 0.82 | POLB (0.64) | RAPGEF4ADRA2AADRA2BADRA2CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015042337-A1 | LUBRICANT COMPOSITIONS FOR DIRECT INJECTION ENGINES | THE LUBRIZOL CORPORATION (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-1801105-B1 | Dibenzo[b]perhydroheterocyclic amines and lubricating oil compositions | CHEVRON ORONITE CO (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7847125-B2 | Acridan derivatives as antioxidants | CHEMTURA CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7847125-B2 | Acridan derivatives as antioxidants | CHEMTURA CORPORATION (US) | 2010-12-07 | — | — | US | disclosed |
| US-7838703-B2 | Diaromatic amine derivatives as antioxidants | CHEMTURA CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838703-B2 | Diaromatic amine derivatives as antioxidants | CHEMTURA CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090131293-A1 | DIAROMATIC AMINE DERIVATIVES AS ANTIOXIDANTS | LANXESS SOLUTIONS US INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131293-A1 | DIAROMATIC AMINE DERIVATIVES AS ANTIOXIDANTS | LANXESS SOLUTIONS US INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131290-A1 | ACRIDAN DERIVATIVES AS ANTIOXIDANTS | LANXESS SOLUTIONS US INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131290-A1 | ACRIDAN DERIVATIVES AS ANTIOXIDANTS | LANXESS SOLUTIONS US INC. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131293-A1 | DIAROMATIC AMINE DERIVATIVES AS ANTIOXIDANTS | CAT, C5, C9 | RAPGEF4 3912/4885ADRA2A 2060/4885ADRA2B 2205/4885 |
| US-20090131290-A1 | ACRIDAN DERIVATIVES AS ANTIOXIDANTS | GPX1, C9, ACR | RAPGEF4 3950/4885ADRA2A 1772/4885ADRA2B 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.